Loading…
Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation
The constant presence of the viral genome in Epstein-Barr virus (EBV)-associated gastric cancers (EBVaGCs) suggests the applicability of novel EBV-targeted therapies. The antiviral nucleoside drug, ganciclovir (GCV), is effective only in the context of the viral lytic cycle in the presence of EBV-en...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Online Article Text |
Language: | English |
Published: |
Impact Journals LLC
2015
|
Subjects: | |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741585/ https://www.ncbi.nlm.nih.gov/pubmed/26427042 |